p38γ mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion

Cancer Research

Volumn 66, Issue 15, 2006, Pages 7540-7547

  Qi, Xiaomei ^a,b   Tang, Jun ^a   Loesch, Mathew ^a,b   Pohl, Nicole ^a,b   Alkan, Serhan ^a   Chen, Guan ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE P38; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; DNA;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INVASION; CELL COMPARTMENTALIZATION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; GROWTH STIMULATION; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; BIOSYNTHESIS; BREAST TUMOR; CELL GROWTH; CELL NUCLEUS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL NUCLEUS; DNA, NEOPLASM; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 12; NEOPLASM INVASIVENESS; PHOSPHORYLATION; RAS PROTEINS; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 33747872178     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4639     Document Type: Article

References (58)

1. Hanahan D, Weiberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004;14:105-14.
3. Gao CF, Xie Q, Su YL, et al. Proliferation and invasion: plasticity in tumor cells. Pro Natl Acad Sci U S A 2005;102:10528-33.
4. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002;4:487-94.
5. Huntington JT, Shields JM, Der CJ. et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells. Role of b-raf mutation and fibroblast growth factor signaling. J Biol Chem 2004;279:33168-76.
6. INK4a and p53. Mol Cell Biol 2004;24:1540-59.
7. Joneson T, White MA, Wigler MH, Bar-Sagi D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of Ras. Science 1996;271:810-2.
8. Roderiguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997;89:457-67.
9. Downward J. Targeting Ras signaling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
10. Fujita T, Kobayashi Y, Wada O, et al. Full activation of estrogen receptor a activation function-1 induces proliferation of breast cancer cells. J Biol Chem 2003;278:26704-14.
11. Pinzone JJ, Stevenson H, Stroble J, Berg PE. Molecular and cellular determinants of estrogen receptor α expression. Mol Cell Biol 2004;24:4605-12.
12. Garcia M, Deroco D, Freiss G, Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Pro Natl Acad Sci U S A 1992;89:11538-42.
13. Platet N, Cunat S, Chalbos D, Rochefort H, Garcia M. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endocrinol 2000;14:999-1009.
14. Clark R, Thompson EW, Leonessa F, et al. Hormone resistance, invasiveness and metastatic potential in breast cancer. Breast Cancer Res Treat 1993;24:227-39.
15. Van't Veer LJ, Dai H, Van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
16. Janda E, Lehmann K, Killisch I, et al. Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002;156:299-313.
17. H DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science 1985;228:725-8.
18. deFazio A, Chiew YE, McEvoy M, Watts CK, Sutherland RL. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells. Cell Growth Differ 1997;8:903-11.
19. Rundle A, Tang D, Brand-Rauf P, et al. Association between the ras p21 oncoprotein in blood samples and breast cancer. Cancer Lett 2002;185:71-8.
20. Ozer E, Sis B, Ozen E, Sakizli M, Canda T, Sarioglu S. BRCA1, C-erbB-2, and H-ras gene expression in young women with breast cancer. An immunohistochemical Study. App Imm Mol Morphol 2000;8:12-8.
21. Mansour S, Matten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-70.
22. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase is necessary and sufficient for PCl2 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77:841-52.
23. Chen G, Hitomi M, Han J, Stacey DW. The p38 pathway provides negative feedback to Ras proliferative signaling. J Biol Chem 2000;275:38973-80.
24. Qi X, Tang J, Pramanik R, et al. p38 MAPK activation selectively induces cell death in K-ras mutated human colon cancer cells through regulation of vitamin D receptor. J Biol Chem 2004;279:22138-44.
25. Bulavin DV, Phillips C, Nannenga B, et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16Ink4a-p19Arf pathway. Nat Genet 2004;36:343-50.
26. Kim MS, Lee EJ, Kim HRC, Moon A. p38 kinase is a key molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res 2003;63:5454-61.
27. Pramanik R, Qi X, Borowicz S, et al. p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun: the determinant role of the isoforms in the p38 MAPK signal specificity. J Biol Chem 2003;278:4831-9.
28. Wang L, Ma R, Flavell R, Choi ME. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for activation of p38α and p38δ MAPK isoforms by TGF-β1 in murine mesangial cells. J Biol Chem 2002;277:42257-62.
29. Ono K, Han J. The p38 signal transduction pathway. Activation and function. Cell Signal 2000;12:1-13.
30. Lechner C, Zahalka MA, Giot J, Moller NP, Ullrich A. ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Pro Natl Acad Sci U S A 1996;93:4355-9.
31. Li Z, Jiang Y, Ulevitch RJ, Han J. The primary structure of p38g: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun 1996;228:334-40.
32. Wang X, McGowan CH, Zhao M, et al. Involvement of the MKK6-38γ cascade in γ-radiation-induced cell cycle arrest. Mol Cell Biol 2000;20:4543-52.
33. Abdollahi T, Robertson NM, Abdollahi A, Litwack G. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Cancer Res 2003;63:4521-6.
34. Tang J, Qi X, Mercola D, Han J, Chen G. Essential role of p38γ in K-Ras transformation independent of phosphorylation. J Biol Chem 2005;280:23910-7.
35. Shu J, Lee JH, Harwalka JA, Oh-Siskovic S, Stacey DW, Golubic M. Adenovirus-mediated gene transfer of dominant negative Ha-Ras inhibits proliferation of primary meningioma cells. Neurosurgery 1999;44:579-88.
36. Hayakawa J, Depatie C, Ohmichi M, Mercola D. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem 2003;278:20582-92.
37. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
38. Zhang CC, Shapiro DJ. Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. J Biol Chem 2000;275:479-86.
39. Lee H, Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 2002;22:5835-45.
40. Qi X, Borowicz S, Pramanik R, Schultz RM, Han J, Chen G. Estrogen receptor inhibits c-Jun-dependent stress-induced cell death by binding and modifying c-Jun activity in human breast cancer cells. J Biol Chem 2004;279:6769-77.
41. Qi X, Pramank R, Wang J, et al. The p38 and JNK pathways cooperate to trans-activate vitamin D receptor via AP-1 and sensitize human breast cancer cells to vitamin D3-induced growth inhibition. J Biol Chem 2002;277:25884-92.
42. Huang S, New L, Pan Z, Han J, Nemerow GR. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38α mitogen-activated protein kinase activity. J Biol Chem 2000;275:12266-72.
43. cip/WAF1 in monocytic differentiation. EMBO J 1999;8:1223-34.
44. Eckert LB, Repasky GA, Ulku AS, et al. Involvement of Ras activation in human breast cancer signaling, invasion, and anoikis. Cancer Res 2004;64:4585-92.
45. H. Cancer Res 1990;50:67-71.
46. Marshall CJ. Ras effectors. Curr Opin Cell Biol 1996;8:197-304.
47. Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogen and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 2004;51:55-67.
48. Oesterreich S, Zhang P, Guler RL, et al. Re-expression of estrogen receptor α in estrogen α-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 2001;61:5771-7.
49. Sabio G, Simon J, Arthur C, et al. p38γ regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J 2005;24:1134-45.
50. Lawrence T, Beblen M, Liu GY, Nizet V, Karin M. IKKα limits macrophage NF-kB activation and contributes to the resolution of inflammation. Nature 2005;434:1138-43.
51. New L, Jiang Y, Han J. Regulation of PRAK subcellular location by p38 MAP kinases. Mol Biol Cell 2003;14:2603-16.
52. Piotrowicz RS, Ding L, Maher P, Levin EG. Inhibition of cell migration by 24-kDa fibroblast growth factor-2 is dependent upon the estrogen receptor. J Biol Chem 2001;276:3963-70.
53. Seternes O, Mikalsen T, Johansen B, et al. Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway. EMBO J 2004;23:4780-91.
54. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. Breast Cancer Res Treat 2000;61:51-62.
55. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001;276:36869-72.
56. Lundy J, Grimson R, Mishriki Y, Chao S, Ovarez S, Fromowitz F. Elevated ras oncogene expression correlates with lymph node metastases in breast cancer patients. J Clin Oncol 1986;4:1321-5.
57. Clair T, Miller W, Cho-Chung Y. Prognostic significance of the expression of the ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 1987;47:3290-3.
58. Malumbres M, Barbacid M. Ras oncogenes: the first 30 years. Nat Rev Cancer 2003;3:7-13.